Synthetic multidomain peptide biomaterials that inhibit inducible nitric oxide synthase
dc.contributor.assignee | Rice University | en_US |
dc.contributor.assignee | Baylor College of Medicine | en_US |
dc.contributor.assignee | The Board of Regents of the University of Texas System | en_US |
dc.contributor.publisher | United States Patent and Trademark Office | en_US |
dc.creator | Hartgerink, Jeffrey | en_US |
dc.creator | Sikora, Andrew G. | en_US |
dc.creator | Leach, David | en_US |
dc.creator | Newton, Jared M. | en_US |
dc.creator | Young, Simon | en_US |
dc.date.accessioned | 2025-04-08T20:23:39Z | en_US |
dc.date.available | 2025-04-08T20:23:39Z | en_US |
dc.date.filed | 2020-12-18 | en_US |
dc.date.issued | 2025-03-18 | en_US |
dc.description.abstract | Provided herein are compositions comprising multi domain peptide (MDP) hydrogels where the peptides that constitute the hydrogel have at least one N6-(1-iminoethyl)-lysine side chain. Also provided are hydrogels that further comprise a STING agonist, an immune checkpoint inhibitor, and/or an anti-cancer therapy. Also provided are methods of using such compositions in the treatment of cancer. | en_US |
dc.digitization.specifications | This patent information was downloaded from the US Patent and Trademark website (http://www.uspto.gov/) as image-PDFs. The PDFs were OCRed for access purposes. | en_US |
dc.format.extent | 47 | en_US |
dc.identifier.patentID | US12251449B2 | en_US |
dc.identifier.uri | https://hdl.handle.net/1911/118301 | en_US |
dc.language.iso | eng | en_US |
dc.title | Synthetic multidomain peptide biomaterials that inhibit inducible nitric oxide synthase | en_US |
dc.type | Utility patent | en_US |
dc.type.dcmi | Text | en_US |
dc.type.genre | patents | en_US |